188 related articles for article (PubMed ID: 32042661)
1. Effect of pimobendan on left atrial function in dogs with preclinical myxomatous mitral valve disease.
Sarcinella F; Neves J; Maddox TW; Hodgkiss-Geere HM; Bode EF; Dukes-McEwan J
Open Vet J; 2020 Jan; 9(4):375-383. PubMed ID: 32042661
[TBL] [Abstract][Full Text] [Related]
2. Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure.
Häggström J; Lord PF; Höglund K; Ljungvall I; Jöns O; Kvart C; Hansson K
J Vet Intern Med; 2013; 27(6):1452-62. PubMed ID: 24128373
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study.
Häggström J; Boswood A; O'Grady M; Jöns O; Smith S; Swift S; Borgarelli M; Gavaghan B; Kresken JG; Patteson M; Åblad B; Bussadori CM; Glaus T; Kovačević A; Rapp M; Santilli RA; Tidholm A; Eriksson A; Belanger MC; Deinert M; Little CJ; Kvart C; French A; Rønn-Landbo M; Wess G; Eggertsdottir A; Lynne O'Sullivan M; Schneider M; Lombard CW; Dukes-McEwan J; Willis R; Louvet A; DiFruscia R
J Vet Intern Med; 2013; 27(6):1441-51. PubMed ID: 24010489
[TBL] [Abstract][Full Text] [Related]
4. Effects of pimobendan on myocardial perfusion and pulmonary transit time in dogs with myxomatous mitral valve disease: a pilot study.
Apple SM; Menciotti G; Braz-Ruivo L; Crosara S; Häggström J; Borgarelli M
Aust Vet J; 2016 Sep; 94(9):324-8. PubMed ID: 27569835
[TBL] [Abstract][Full Text] [Related]
5. Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial.
Boswood A; Häggström J; Gordon SG; Wess G; Stepien RL; Oyama MA; Keene BW; Bonagura J; MacDonald KA; Patteson M; Smith S; Fox PR; Sanderson K; Woolley R; Szatmári V; Menaut P; Church WM; O'Sullivan ML; Jaudon JP; Kresken JG; Rush J; Barrett KA; Rosenthal SL; Saunders AB; Ljungvall I; Deinert M; Bomassi E; Estrada AH; Fernandez Del Palacio MJ; Moise NS; Abbott JA; Fujii Y; Spier A; Luethy MW; Santilli RA; Uechi M; Tidholm A; Watson P
J Vet Intern Med; 2016 Nov; 30(6):1765-1779. PubMed ID: 27678080
[TBL] [Abstract][Full Text] [Related]
6. Left atrial volume and function in dogs with naturally occurring myxomatous mitral valve disease.
Höllmer M; Willesen JL; Tolver A; Koch J
J Vet Cardiol; 2017 Feb; 19(1):24-34. PubMed ID: 27825670
[TBL] [Abstract][Full Text] [Related]
7. Effect of standard-dose and high-dose pimobendan on select indices of renal and cardiac function in dogs with American College of Veterinary Internal Medicine stage B2 myxomatous mitral valve disease.
Kaplan JL; Visser LC; Gunther-Harrington CT; Ontiveros ES; Wittenburg LA; Palm CA; Stern JA
J Vet Intern Med; 2022 Nov; 36(6):1892-1899. PubMed ID: 36098206
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study.
Boswood A; Gordon SG; Häggström J; Wess G; Stepien RL; Oyama MA; Keene BW; Bonagura J; MacDonald KA; Patteson M; Smith S; Fox PR; Sanderson K; Woolley R; Szatmári V; Menaut P; Church WM; O'Sullivan ML; Jaudon JP; Kresken JG; Rush J; Barrett KA; Rosenthal SL; Saunders AB; Ljungvall I; Deinert M; Bomassi E; Estrada AH; Fernandez Del Palacio MJ; Moise NS; Abbott JA; Fujii Y; Spier A; Luethy MW; Santilli RA; Uechi M; Tidholm A; Schummer C; Watson P
J Vet Intern Med; 2018 Jan; 32(1):72-85. PubMed ID: 29214723
[TBL] [Abstract][Full Text] [Related]
9. The longitudinal outcome of canine (K9) myxomatous mitral valve disease (LOOK-Mitral) registry: Baseline treatment characteristics.
Franchini A; Borgarelli M; Abbott JA; Menciotti G; Crosara S; Häggström J; Lahmers S; Rosenthal S; Tyrrell W
J Vet Cardiol; 2022 Jun; 41():99-120. PubMed ID: 35316716
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of pimobendan after oral administration to dogs with myxomatous mitral valve disease.
McManamey AK; DeFrancesco TC; Meurs KM; Papich MG
J Vet Intern Med; 2023; 37(6):2003-2010. PubMed ID: 37776546
[TBL] [Abstract][Full Text] [Related]
11. Effect of pimobendan on the incidence of arrhythmias in small breed dogs with myxomatous mitral valve degeneration.
Lake-Bakaar GA; Singh MK; Kass PH; Griffiths LG
J Vet Cardiol; 2015 Jun; 17(2):120-8. PubMed ID: 26007710
[TBL] [Abstract][Full Text] [Related]
12. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study.
Häggström J; Boswood A; O'Grady M; Jöns O; Smith S; Swift S; Borgarelli M; Gavaghan B; Kresken JG; Patteson M; Ablad B; Bussadori CM; Glaus T; Kovacević A; Rapp M; Santilli RA; Tidholm A; Eriksson A; Belanger MC; Deinert M; Little CJ; Kvart C; French A; Rønn-Landbo M; Wess G; Eggertsdottir AV; O'Sullivan ML; Schneider M; Lombard CW; Dukes-McEwan J; Willis R; Louvet A; DiFruscia R
J Vet Intern Med; 2008; 22(5):1124-35. PubMed ID: 18638016
[TBL] [Abstract][Full Text] [Related]
13. Effect of pimobendan on physical fitness, lactate and echocardiographic parameters in dogs with preclinical mitral valve disease without cardiomegaly.
Iwanuk N; Wall L; Nolte I; Raue J; Rumstedt K; Pilgram A; Sehn M; Rohn K; Bach JP
PLoS One; 2019; 14(10):e0223164. PubMed ID: 31581204
[TBL] [Abstract][Full Text] [Related]
14. Left atrial deformation and phasic function determined by two-dimensional speckle-tracking echocardiography in dogs with myxomatous mitral valve disease.
Caivano D; Rishniw M; Birettoni F; Patata V; Giorgi ME; Porciello F
J Vet Cardiol; 2018 Apr; 20(2):102-114. PubMed ID: 29459124
[TBL] [Abstract][Full Text] [Related]
15. Effect of Pimobendan on NT-proBNP and c troponin I before and after a submaximal exercise test in dogs with preclinical mitral valve disease without cardiomegaly - a randomised, double-blinded trial.
Iwanuk N; Nolte I; Wall L; Sehn M; Raue J; Pilgram A; Rumstedt K; Bach JP
BMC Vet Res; 2019 Jul; 15(1):237. PubMed ID: 31288807
[TBL] [Abstract][Full Text] [Related]
16. Impact of a combination of pimobendan, furosemide, and enalapril on heart rate variability in naturally occurring, symptomatic, myxomatous mitral valve degeneration dogs.
Pirintr P; Saengklub N; Boonpala P; Hamlin RL; Kijtawornrat A
BMC Vet Res; 2023 Oct; 19(1):201. PubMed ID: 37821927
[TBL] [Abstract][Full Text] [Related]
17. Two-dimensional echocardiographic estimates of left atrial function in healthy dogs and dogs with myxomatous mitral valve disease.
Dickson D; Caivano D; Matos JN; Summerfield N; Rishniw M
J Vet Cardiol; 2017 Dec; 19(6):469-479. PubMed ID: 29111284
[TBL] [Abstract][Full Text] [Related]
18. Left Atrial Strain at Different Stages of Myxomatous Mitral Valve Disease in Dogs.
Nakamura K; Kawamoto S; Osuga T; Morita T; Sasaki N; Morishita K; Ohta H; Takiguchi M
J Vet Intern Med; 2017 Mar; 31(2):316-325. PubMed ID: 28145607
[TBL] [Abstract][Full Text] [Related]
19. Echocardiographic parameters for the assessment of congestive heart failure in dogs with myxomatous mitral valve disease and moderate to severe mitral regurgitation.
Morgan KRS; Monteith G; Raheb S; Colpitts M; Fonfara S
Vet J; 2020 Sep; 263():105518. PubMed ID: 32928487
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of echocardiographic indices of left atrial morphology and function in dogs with myxomatous mitral valve disease.
Baron Toaldo M; Romito G; Guglielmini C; Diana A; Pelle NG; Contiero B; Cipone M
J Vet Intern Med; 2018 May; 32(3):914-921. PubMed ID: 29572938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
